Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect.

Date publication

février 2021

Journal

Oncoimmunology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard

Tous les auteurs :
Janikashvili N, Gérard C, Thébault M, Brazdova A, Boibessot C, Cladière C, Ciudad M, Greigert H, Ouandji S, Ghesquière T, Samson M, Audia S, Saas P, Bonnotte B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33659098

Résumé

Immunosuppressive cell-based therapy is a recent strategy for controlling Graft--Host Disease (GvHD). Such cells ought to maintain their suppressive function in inflammatory conditions and in the presence of immunosuppressive agents currently used in allogeneic hematopoietic cell transplantation (allo-HCT). Moreover, these therapies should not diminish the benefits of allo-HCT, the Graft--Leukemia (GvL) effect. We have previously reported on a novel subset of human monocyte-derived suppressor cells (HuMoSC) as a prospective approach for controlling GvHD.Objective.

Mots clés

Human monocyte-derived suppressor cells, graft-versus-host disease, graft-versus-leukemia effect, immunosuppressive drugs, inflammation, regulatory T cells

Référence

Oncoimmunology. 2021 Feb 19;10(1):1880046